TY - JOUR
T1 - Sexual dysfunction and cardiac risk (the Second Princeton Consensus Conference)
AU - Kostis, John B.
AU - Jackson, Graham
AU - Rosen, Raymond
AU - Barrett-Connor, Elizabeth
AU - Billups, Kevin
AU - Burnett, Arthur L.
AU - Carson, Culley
AU - Cheitlin, Melvin
AU - Debusk, Robert
AU - Fonseca, Vivian
AU - Ganz, Peter
AU - Goldstein, Irwin
AU - Guay, Andre
AU - Hatzichristou, Dimitris
AU - Hollander, Judd E.
AU - Hutter, Adolph
AU - Katz, Stuart
AU - Kloner, Robert A.
AU - Mittleman, Murray
AU - Montorsi, Francesco
AU - Montorsi, Piero
AU - Nehra, Ajay
AU - Sadovsky, Richard
AU - Shabsigh, Ridwan
N1 - Funding Information:
The First Princeton Consensus Conference was convened in June 1999 to evaluate the scientific evidence regarding sexual activity and cardiac risk and to develop practice guidelines for the management of erectile dysfunction (ED) in patients with significant cardiac risk. 1 Recent epidemiologic studies have underscored the associations among endothelial dysfunction, cardiovascular risk factors, and sexual dysfunction, and more knowledge on phosphodiesterase (PDE)-5 inhibitors has accumulated. 2–12 The Second Princeton Consensus Conference on sexual dysfunction and cardiac risk was convened in June 2004 in Princeton, New Jersey. The conference was sponsored by the University of Medicine and Dentistry of New Jersey-Robert Wood Johnson Medical School, in collaboration with the International Society for Sexual Medicine, the European Society for Sexual Medicine, and the Sexual Medicine Society of North America. On the first day, an international panel of experts provided state-of-the-art presentations on aspects of ED and cardiac risk. The full text of these presentations is available in a special supplement to the journal. On the second day of the conference, the consensus panel met in closed session to review and evaluate available evidence and to make recommendations for clinical management.
Funding Information:
The Second Princeton Consensus Conference was supported by unrestricted educational grants from Pfizer Inc., New York, New York; Lilly/ICOS LLC, Bothell, Washington; Vivus, Palo Alto, California; Solvay, Marietta, Georgia; and Sanofi-Synthelabo, Bridgewater, New Jersey.
PY - 2005/7/15
Y1 - 2005/7/15
N2 - Recent studies have highlighted the relation between erectile dysfunction (ED) and cardiovascular disease. In particular, the role of endothelial dysfunction and nitric oxide in ED and atherosclerotic disease has been elucidated. Given the large number of men receiving medical treatment for ED, concerns regarding the risk for sexual activity triggering acute cardiovascular events and potential risks of adverse or unanticipated drug interactions need to be addressed. A risk stratification algorithm was developed by the First Princeton Consensus Panel to evaluate the degree of cardiovascular risk associated with sexual activity for men with varying degrees of cardiovascular disease. Patients were assigned to 3 categories: low, intermediate (including those requiring further evaluation), and high risk. This consensus study from the Second Princeton Consensus Conference corroborates and clarifies the algorithm and emphasizes the importance of risk factor evaluation and management for all patients with ED. The panel reviewed recent safety and drug interaction data for 3 phosphodiesterase (PDE)-5 inhibitors (sildenafil, tadalafil, vardenafil), with emphasis on the safety of these agents in men with ED and concomitant cardiovascular disease. Increasing evidence supports the role of lifestyle intervention in ED, specifically weight loss and increased physical activity, particularly in patients with ED and concomitant cardiovascular disease. Special management recommendations for patients taking PDE-5 inhibitors who present at the emergency department and other emergency medical situations are described. Finally, further research on the role of PDE-5 inhibition in treating patients with other medical or cardiovascular disorders is recommended.
AB - Recent studies have highlighted the relation between erectile dysfunction (ED) and cardiovascular disease. In particular, the role of endothelial dysfunction and nitric oxide in ED and atherosclerotic disease has been elucidated. Given the large number of men receiving medical treatment for ED, concerns regarding the risk for sexual activity triggering acute cardiovascular events and potential risks of adverse or unanticipated drug interactions need to be addressed. A risk stratification algorithm was developed by the First Princeton Consensus Panel to evaluate the degree of cardiovascular risk associated with sexual activity for men with varying degrees of cardiovascular disease. Patients were assigned to 3 categories: low, intermediate (including those requiring further evaluation), and high risk. This consensus study from the Second Princeton Consensus Conference corroborates and clarifies the algorithm and emphasizes the importance of risk factor evaluation and management for all patients with ED. The panel reviewed recent safety and drug interaction data for 3 phosphodiesterase (PDE)-5 inhibitors (sildenafil, tadalafil, vardenafil), with emphasis on the safety of these agents in men with ED and concomitant cardiovascular disease. Increasing evidence supports the role of lifestyle intervention in ED, specifically weight loss and increased physical activity, particularly in patients with ED and concomitant cardiovascular disease. Special management recommendations for patients taking PDE-5 inhibitors who present at the emergency department and other emergency medical situations are described. Finally, further research on the role of PDE-5 inhibition in treating patients with other medical or cardiovascular disorders is recommended.
UR - http://www.scopus.com/inward/record.url?scp=22144467731&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=22144467731&partnerID=8YFLogxK
U2 - 10.1016/j.amjcard.2005.03.065
DO - 10.1016/j.amjcard.2005.03.065
M3 - Article
C2 - 16018863
AN - SCOPUS:22144467731
SN - 0002-9149
VL - 96
SP - 313
EP - 321
JO - American Journal of Cardiology
JF - American Journal of Cardiology
IS - 2
ER -